FDA resurrects compounding advisory panel
This article was originally published in Scrip
Executive Summary
More than a decade after the FDA dissolved its advisory committee on pharmacy compounding, the agency has resurrected the panel – although, this time with some new members, whose identities were revealed on 16 December.